Dummer, R; Gusenleitner, D; Campbell, CD; Lebbe, C; Atkinson, V; Mandala, M; Nathan, PD; Arance, A; Richtig, E; Yamazaki, N; Robert, C; Schadendorf, D; Tawbi, HAH; Ascierto, PA; Ribas, A; Flaherty, K; Gasal, E; Brase, JC; Long, GV.
Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma treated with first-line spartalizumab (S) plus dabrafenib (D) plus trametinib (T).
J CLIN ONCOL. 2019; 37(15):
Doi: 10.1200/JCO.2019.37.15_suppl.9515
[Poster]
Web of Science
FullText
FullText_MUG